Read Article : Eli Lilly Humalog Has 3,5 Billion Revenue and BIOD Has Better Results. POST.
BioPharma Catalyst Trade Pick Of The Week: Biodel By: Scott Matusow
Biodel chose Eli Lilly's (LLY) Humalog as its comparator for BIOD-123 and in Phase I trials has shown very positive results. BIOD-123 showed a better pharmacokinetic profile (PK) than Humalog and an improvement in injection site tolerability - Humalog (along with Humilin) brings in yearly sales for Lilly of over $3.5B